Market report: Cancer test breakthrough sparks UK biotech Oxford BioMedica
A big breakthrough in cancer treatment could be on the cards as the FDA's advisory committee backs the tumour investigation therapy CTL019, developed by Novartis. This is superb news for the UK's Oxford BioMedica (OXB), whose...
13 July 2017
